ImmuCell Corp ICCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
-
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
-
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
-
ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 9.08M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 121.37
- Price/Sales
- 3.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 73
- Website
- https://www.immucell.com
Valuation
|
Metric
|
ICCC
|
|---|---|
Price/Earnings (Normalized) | 121.37 |
Price/Book Value | 3.00 |
Price/Sales | 3.07 |
Price/Cash Flow | 14.79 |
Price/Earnings
ICCC
Financial Strength
|
Metric
|
ICCC
|
|---|---|
Quick Ratio | 2.65 |
Current Ratio | 4.75 |
Interest Coverage | 2.69 |
Quick Ratio
ICCC
Profitability
|
Metric
|
ICCC
|
|---|---|
Return on Assets (Normalized) | 8.54% |
Return on Equity (Normalized) | 13.09% |
Return on Invested Capital (Normalized) | 9.49% |
Return on Assets
ICCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<KVfT%p | LOCK|GT?j | $139B | |||
| Moderna Inc
MRNA
| LOCK|Yhj@@Q | LOCK|htb | $103B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@j<@<y< | LOCK|L!VWy | $96B | |||
| argenx SE ADR
ARGX
| LOCK|K$kt>@ | LOCK|P< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|BKcSYwQ | LOCK|jb | $45B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xt@?F@B | LOCK|r>Lp | $30B | |||
| Incyte Corp
INCY
| LOCK|>k^Q&&K | LOCK|Yf$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|HRz?FMs | LOCK|gd! | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|nGVd&M? | LOCK|?%gy | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|w@?lkQ> | LOCK|kj% | $15B |
United States